Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (24068)	8/6/1998 1:39:00 PM
From: Machaon	Respond to of 32384

<< Ligand believes a sales force of 22 oncology sales specialists will be sufficient to launch the first product, and 35 should be adequate for the first four or five oncology products in the U.S. Similar numbers are projected for Europe. >> It'll be interesting to see how well Ligand executes it's business plan. Even though the fall in Ligand's stock price hasn't been pleasant, we are nearing the probable beginning their revenue growth, and significant product growth. Let's hope that the institutions start accumulating the low priced biotechs. I guess the way to determine that this is happening, would be to see increased volume with little or no movement up in the stock price. Regards, Bob